Intra-arterial chemotherapy for retinoblastoma. Challenges of a prospective study

Acta Ophthalmologica

Volumn 92, Issue 3, 2014, Pages 209-215

  Parareda, Andreu ^a   Català, Jaume ^a   Carcaboso, Angel M ^a   Sola, Teresa ^b   Cruz, Ofelia ^a   Díaz, Jesús ^a   Salvador, Héctor ^a   De Torres, Carmen ^a   Álvarez Sampons, Alexandra ^a   Suñol, Mariona ^a   Vinent, Joan ^a   Guimaraens, Leopoldo ^b   Prat, Joan ^a   Mora, Jaume ^a  

^a HOSPITAL SANT JOAN DE DÉU   (Spain)

^b HOSPITAL GENERAL DE CATALUNYA   (Spain)

Author keywords

clinical trial; intraarterial chemotherapy; melphalan; retinoblastoma

Indexed keywords

MELPHALAN; ALKYLATING AGENT;

ANTINEOPLASTIC ACTIVITY; ARTERIOLOSCLEROSIS; ARTICLE; BRACHYTHERAPY; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CHILD; CLINICAL ARTICLE; DRUG EFFICACY; DRUG SAFETY; ENUCLEATION; EYELID EDEMA; HUMAN; HUMAN TISSUE; INTRAOCULAR FOREIGN BODY; MACROPHAGE; MICROCATHETER; MULTINUCLEAR CELL; ORBIT EDEMA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROSPECTIVE STUDY; PTOSIS; REPRODUCIBILITY; RETINA DISEASE; RETINA HYPERPIGMENTATION; RETINA MACULA DEGENERATION; RETINOBLASTOMA; SALVAGE THERAPY; TREATMENT OUTCOME; CLINICAL TRIAL; DOSE RESPONSE; EYE FUNDUS; FEMALE; FLUORESCENCE ANGIOGRAPHY; FOLLOW UP; INFANT; INTRAARTERIAL DRUG ADMINISTRATION; MALE; MULTICENTER STUDY; NEWBORN; OPHTHALMIC ARTERY; PRESCHOOL CHILD; RETINAL NEOPLASMS; TIME;

ANTINEOPLASTIC AGENTS, ALKYLATING; CHILD, PRESCHOOL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FLUORESCEIN ANGIOGRAPHY; FOLLOW-UP STUDIES; FUNDUS OCULI; HUMANS; INFANT; INFANT, NEWBORN; INJECTIONS, INTRA-ARTERIAL; MALE; MELPHALAN; OPHTHALMIC ARTERY; PROSPECTIVE STUDIES; RETINAL NEOPLASMS; RETINOBLASTOMA; TIME FACTORS; TREATMENT OUTCOME;

EID: 84899459616     PISSN: 1755375X     EISSN: 17553768     Source Type: Journal    
DOI: 10.1111/aos.12295     Document Type: Article

References (27)

1. Abramson DH, (2011): Chemosurgery for retinoblastoma: what we know after 5 years. Arch Ophthalmol 129: 1492-1494.
2. Abramson DH, Dunkel IJ, Brodie SE, Kim JW, &, Gobin YP, (2008): A phase I/II study of direct intraarterial (ophthalmic artery) chemotherapy with melphalan for intraocular retinoblastoma initial results. Ophthalmology, 115: 1398-1404. 1404.e139.
3. Abramson DH, Marr BP, Brodie SE, Dunkel I, Palioura S, &, Gobin YP, (2012): Ophthalmic artery chemosurgery for less advanced intraocular retinoblastoma: five year review. PLoS ONE 7: e34120.
4. Bianciotto C, Shields CL, Iturralde JC, Sarici A, Jabbour P, &, Shields JA, (2012): Fluorescein angiographic findings after intra-arterial chemotherapy for retinoblastoma. Ophthalmology 119: 843-849.
5. Chantada GL, Gonzalez A, Fandino A, de Davila MT, Demirdjian G, Scopinaro M, &, Abramson D, (2009): Some clinical findings at presentation can predict high-risk pathology features in unilateral retinoblastoma. J Pediatr Hematol Oncol 31: 325-329.
6. van Dijk J, Huisman J, Moll AC, Schouten-van Meeteren AY, Bezemer PD, Ringens PJ, Cohen-Kettenis PT, &, Imhof SM, (2007): Health-related quality of life of child and adolescent retinoblastoma survivors in the Netherlands. Health Qual Life Outcomes 5: 65.
7. Eagle RC Jr, Shields CL, Bianciotto C, Jabbour P, &, Shields JA, (2011): Histopathologic observations after intra-arterial chemotherapy for retinoblastoma. Arch Ophthalmol 129: 1416-1421.
8. Gobin YP, Dunkel IJ, Marr BP, Brodie SE, &, Abramson DH, (2011): Intra-arterial chemotherapy for the management of retinoblastoma: four-year experience. Arch Ophthalmol 129: 732-737.
9. Jabbour P, Chalouhi N, Tjoumakaris S, et al. (2012): Pearls and pitfalls of intraarterial chemotherapy for retinoblastoma. J Neurosurg Pediatr 10: 175-181.
10. Kaliki S, Shields CL, Rojanaporn D, Al-Dahmash S, McLaughlin JP, Shields JA, Eagle RC Jr, (2013): High-risk retinoblastoma based on international classification of retinoblastoma: analysis of 519 enucleated eyes. Ophthalmology 120: 997-1003.
11. Levin MH, Gombos DS, &, O'Brien JM, (2011): Intra-arterial chemotherapy for advanced retinoblastoma: is the time right for a prospective clinical trial? Arch Ophthalmol 129: 1487-1489.
12. Lohmann D, (2010): Retinoblastoma. Adv Exp Med Biol 685: 220-227.
13. Marr BP, Brodie SE, Dunkel IJ, Gobin YP, &, Abramson DH, (2012): Three-drug intra-arterial chemotherapy using simultaneous carboplatin, topotecan and melphalan for intraocular retinoblastoma: preliminary results. Br J Ophthalmol 96: 1300-1303.
14. Materin MA, Kuzmik GA, Jubinsky PT, Minja FJ, Asnes JD, &, Bulsara KR, (2013): Verification of supraselective drug delivery for retinoblastoma using intra-arterial gadolinium. J Neurointerv Surg 5: e42.
15. Muen WJ, Kingston JE, Robertson F, Brew S, Sagoo MS, &, Reddy MA, (2012): Efficacy and complications of super-selective intra-ophthalmic artery melphalan for the treatment of refractory retinoblastoma. Ophthalmology 119: 611-616.
16. Munier FL, Beck-Popovic M, Balmer A, Gaillard MC, Bovey E, &, Binaghi S, (2011): Occurrence of sectoral choroidal occlusive vasculopathy and retinal arteriolar embolization after superselective ophthalmic artery chemotherapy for advanced intraocular retinoblastoma. Retina 31: 566-573.
17. Murphree LA, (2005): Intraocular retinoblastoma: the case for a new group classification. Ophthalmol Clin North Am 18: 41-53.
18. Schaiquevich P, Ceciliano A, Millan N, Taich P, Villasante F, Fandino AC, Dominguez J, &, Chantada GL, (2013): Intra-arterial chemotherapy is more effective than sequential periocular and intravenous chemotherapy as salvage treatment for relapsed retinoblastoma. Pediatr Blood Cancer 60: 766-770.
19. Shields CL, Bianciotto CG, Jabbour P, Griffin GC, Ramasubramanian A, Rosenwasser R, &, Shields JA, (2011a): Intra-arterial chemotherapy for retinoblastoma: report No. 2, treatment complications. Arch Ophthalmol 129: 1407-1415.
20. Shields CL, Bianciotto CG, Jabbour P, Ramasubramanian A, Lally SE, Griffin GC, Rosenwasser R, &, Shields JA, (2011b): Intra-arterial chemotherapy for retinoblastoma: report No. 1, control of retinal tumors, subretinal seeds, and vitreous seeds. Arch Ophthalmol 129: 1399-1406.
21. Steinle JJ, Zhang Q, Thompson KE, et al. (2012): Intra-ophthalmic artery chemotherapy triggers vascular toxicity through endothelial cell inflammation and leukostasis. Invest Ophthalmol Vis Sci 53: 2439-2445.
22. Suzuki S, Yamane T, Mohri M, &, Kaneko A, (2011): Selective ophthalmic arterial injection therapy for intraocular retinoblastoma: the long-term prognosis. Ophthalmology 118: 2081-2087.
23. Vajzovic LM, Murray TG, Aziz-Sultan MA, Schefler AC, CE, Wolfe SC, Hess DJ, &, Dubovy SR, (2010): Clinicopathologic review of enucleated eyes after intra-arterial chemotherapy with melphalan for advanced retinoblastoma. Arch Ophthalmol 128: 1619-1623.
24. Valero Garcia S, Lopez Briz E, Escobar Cava P, Balaguer J, Pelufo A, Megias JE, &, Poveda Andres JL, (2013): Selective ophthalmic intra-arterial melphalan therapy for advanced retinoblastoma: implementation and outcomes of a new chemotherapy protocol. J Oncol Pharm Pract 19: 159-164.
25. Venturi C, Bracco S, Cerase A, et al. (2013): Superselective ophthalmic artery infusion of melphalan for intraocular retinoblastoma: preliminary results from 140 treatments. Acta Ophthalmol 91: 335-342.
26. Wilson MW, Haik BG, &, Dyer MA, (2011a): Superselective intraophthalmic artery chemotherapy: what we do not know. Arch Ophthalmol 129: 1490-1491.
27. Wilson MW, Jackson JS, Phillips BX, et al. (2011b): Real-time ophthalmoscopic findings of superselective intraophthalmic artery chemotherapy in a nonhuman primate model. Arch Ophthalmol 129: 1458-1465.